



August 2006

POCT₀₄-A₂

Point-of-Care *In Vitro* Diagnostic (IVD) Testing; Approved Guideline—Second Edition

This document provides guidance to users of *in vitro* diagnostic (IVD) devices outside the clinical laboratory, to ensure reliable results comparable to those obtained within the clinical laboratory.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

ISBN 1-56238-618-2
ISSN 0273-3099

POCT04-A2
Vol. 26 No. 30
Replaces AST2-A
Vol. 19 No. 9

Point-of-Care *In Vitro* Diagnostic (IVD) Testing; Approved Guideline— Second Edition

Volume 26 Number 30

Ellis Jacobs, PhD, DABCC, FACB
Judy C. Arbique, ART(CSMLS)CLS(NCA)
Louis J. Dunka, Jr., PhD
Cheryl Hackett, MT(ASCP)
Lisa R. Henderson, MPA, MT(ASCP), NCA
Barbara Mitchell
T. Andrew Quintenz
Kathy Scruggs, MT(ASCP)
Kathleen E. Steffens, MA, MT(ASCP)
Patrick J. St. Louis, PhD, DipCC

Abstract

Clinical and Laboratory Standards Institute document POCT04-A2—*Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline—Second Edition* provides users of *in vitro* diagnostic (IVD) devices outside the clinical laboratory with information and suggestions for good laboratory practice and for producing reliable test results regardless of where the test is performed. Point-of-care testing (POCT), also known as bedside testing or near-patient testing, is intended to provide more rapid test results than can be achieved in central or satellite laboratory settings. This is important particularly in critical care areas, such as the intensive care unit, emergency rooms, burn units, emergency transport vehicles, and operating rooms, as well as in skilled nursing facilities and hospices. POCT has also been used to expedite treatment decisions and provide convenience for the patient/client.

Clinical and Laboratory Standards Institute (CLSI). *Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline—Second Edition*. Clinical and Laboratory Standards Institute document POCT04-A2 (ISBN 1-56238-618-2). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2006.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



Copyright ©2006 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline—Second Edition*. CLSI document POCT04-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.

Proposed Guideline

March 1995

Approved Guideline

June 1999

Approved Guideline—Second Edition

August 2006

ISBN 1-56238-618-2
ISSN 0273-3099

Committee Membership

Area Committee on Point-of-Care Testing

Louis J. Dunka, Jr., PhD
Chairholder
LifeScan, Inc.
Milpitas, California

James H. Nichols, PhD, DABCC, FACB
Vice-Chairholder
Baystate Medical Center
Springfield, Massachusetts

Diana R. DeHoyos, MS,
 MT(ASCP)
 The University of Texas Medical
 Branch
 Galveston, Texas

Christopher Fetters
 NOVA Biomedical
 Waltham, Massachusetts

George W. Gaebler, III, MSED,
 RRT, FAARC
 University Hospital
 Syracuse, New York

Ethan D. Hausman, MD, FAAP,
 FCAP
 FDA Center for Devices and
 Radiological Health
 Rockville, Maryland

Frank LaDuca, PhD
 Bayer HealthCare, Diagnostics
 Division
 Tarrytown, New York

Raelene M. Perfetto, MBA,
 MT(ASCP)
 Centers for Medicare & Medicaid
 Services
 Baltimore, Maryland

Kathy Scruggs, MT(ASCP)
 Dayton VA Medical Center
 Dayton, Ohio

Patrick J. St. Louis, PhD, DipCC
 Ste. Justine Hospital
 Montreal, Quebec, Canada

Advisors

Jeff Dahlen, PhD
 Biosite Incorporated
 San Diego, California

Sharon S. Ehrmeyer, PhD
 University of Wisconsin
 Madison, Wisconsin

Valerio M. Genta, MD
 Sentara Virginia Beach General
 Hospital
 Virginia Beach, Virginia

Barry H. Ginsberg, MD, PhD
 BD
 Franklin Lakes, New Jersey

Ellis Jacobs, PhD, DABCC, FACB
 New York State Dept. of Health
 Albany, New York

David Klonoff, MD
 Diabetes Technology Society
 Foster City, California

Katsuhiko Kuwa, PhD
 University of Tsukuba
 Tsukuba, Japan

Ronald H. Ng, PhD, DABCC,
 FACB
 Abbott Diabetes Care
 Alameda, California

Carmina Pascual, MT(ASCP),
 CLS(NCA)
 Roche Instrument Center AG
 Rotkreuz, Switzerland

David L. Phillips
 HemoSense, Inc.
 San Jose, California

Paula J. Santrach, MD
 Mayo Clinic
 Rochester, Minnesota

Lou Ann Wyer, MT(ASCP)
 Sentara Healthcare
 Norfolk, Virginia

Subcommittee on Point-of-Care IVD Testing

Ellis Jacobs, PhD, DABCC, FACB
Chairholder
New York State Dept. of Health
Albany, New York

Judy C. Arbique,
 ART(CSMLS)CLS(NCA)
 Arbique-Rendell Onsite Training &
 Consulting
 Halifax, Nova Scotia, Canada

Jeff Dahlen, PhD
 Biosite Incorporated
 San Diego, California

Cheryl Hackett, MT(ASCP)
 George Washington University
 Hospital
 Washington, District of Columbia

Lisa R. Henderson, MPA,
 MT(ASCP), NCA
 American Academy of Family
 Physicians
 Leawood, Kansas

Kirsten Kempe, PhD
 LifeScan, Inc.
 Milpitas, California

Kathleen E. Steffens, MA,
 MT(ASCP)
 JCAHO
 Oakbrook Terrace, Illinois

Advisors

Louis J. Dunka, Jr., PhD
 LifeScan, Inc.
 Milpitas, California

Louise Jackman
 COLA
 Columbia, Maryland

Ronald H. Ng, PhD, DABCC,
 FACB
 Abbott Diabetes Care
 Alameda, California

Luann Ochs, MS
 Roche Diagnostics Corporation
 Indianapolis, Indiana

Advisors (Continued)

Donald R. Parker, PhD
Bayer Healthcare, LLC
Elkhart, Indiana

Patrick J. St. Louis, PhD, DipCC
Ste. Justine Hospital
Montreal, Quebec, Canada

Staff

Clinical and Laboratory Standards
Institute
Wayne, Pennsylvania

John J. Zlockie, MBA
Vice President, Standards

David E. Sterry, MT(ASCP)
Staff Liaison

Donna M. Wilhelm
Editor

Melissa A. Lewis
Assistant Editor

Acknowledgement

CLSI gratefully acknowledges the contributions of the late Dr. Louis J. Dunka, Jr., LifeScan, Inc., who served as the Chairholder of the Area Committee on Point-of-Care Testing and was an active participant on the Subcommittee on Point-of-Care IVD Testing during the revision of this document.

Contents

Abstract.....i

Committee Membership..... iii

Foreword.....ix

1 Scope..... 1

2 Introduction..... 1

3 Standard Precautions..... 1

4 Definitions 1

 4.1 Abbreviations and Acronyms 6

5 POCT Consideration..... 7

6 Regulatory Considerations..... 8

7 Development of Policy 8

 7.1 Designate Authority 9

 7.2 Assign Responsibility 9

 7.3 Maintain Accountability 10

8 Procedures..... 10

9 Organizational Structure 10

 9.1 Hospital-Based POCT..... 11

 9.2 Nonhospital-Based POCT..... 13

10 Personnel Considerations..... 13

 10.1 Hospital Setting..... 14

 10.2 POCT Personnel Outside the Hospital..... 15

11 Method and Instrument Considerations and Selection 16

 11.1 Gathering Information 16

 11.2 Beginning the Process..... 17

12 Training..... 19

13 Cost Accounting Considerations..... 20

14 Cost/Benefit Analysis 22

15 Safety and Waste Disposal..... 23

 15.1 Safety 23

 15.2 Exposure-Incident Follow-up 23

 15.3 Avoiding Accidental Skin Puncture With Sharps..... 23

 15.4 Personal Protective Equipment 23

 15.5 Handwashing/Sanitizing 24

 15.6 Food, Drink, Cigarettes, and Cosmetics 24

Contents (Continued)

15.7	Routine Cleaning and Disposal.....	24
15.8	Infectious Waste Handling and Disposal.....	25
15.9	Electrical Precautions	25
15.10	Safety Manual.....	25
16	Patient/Client Preparation/Specimen Collection and Identification	25
16.1	Patient/Client Preparation and Identification.....	25
16.2	Specimen Collection.....	26
16.3	Specimen Identification.....	26
16.4	Special Precautions.....	27
17	Calibration and Calibration Verification.....	27
17.1	Calibration	27
17.2	Calibration Verification.....	28
17.3	Frequency of Calibration and Calibration Verification	28
18	Quality Control	29
18.1	Purpose of Controls	29
18.2	Applicability of QC Procedures.....	29
18.3	Considerations in Designing a QC Program.....	30
18.4	Guidelines for QC Applied to Various Testing Devices.....	31
19	Reportable Range.....	32
20	Maintenance.....	32
21	Evaluation/Surveillance of Proficiency	33
22	Result Reporting/Recordkeeping.....	33
22.1	Confidentiality	33
22.2	Reporting and Forms	33
22.3	Reporting Test Results.....	34
22.4	Medical Alert Values.....	35
23	Interpretation of Results.....	35
24	Quality Control Documentation.....	36
24.1	QC Documentation	36
25	Quality Assurance.....	36
25.1	General Recommendations for QA.....	37
25.2	QA Documentation.....	37
26	Risk Management/Liability	38
	References.....	39
	Additional References.....	40
	Appendix A. Sample Procedure Format	41
	Appendix B. Sample QC Log Sheet	43

Contents (Continued)

Appendix C. Sample Preventive Maintenance Record Form44

Appendix D. Sources for Practice Parameters and American College of Physicians Guidelines.....45

Appendix E. Point-of-Care Training Checklist.....46

Summary of Delegate Comments and Subcommittee Responses.....47

The Quality System Approach.....52

Related CLSI/NCCLS Publications53

Foreword

As a result of pressures from outside and within, the healthcare community is reevaluating how to best deliver services to society in a complex healthcare system. Part of this examination concerns the delivery of laboratory services to patients/clients.

Medical conditions, physical location of the patient/client, and treatment regimens often require laboratory results to be obtained quickly, so appropriate medical care can be administered without delay. Laboratory medicine professionals have been challenged by the increasing demands for faster turnaround of results, but at the same time are faced with limitations in providing these services, imposed in part by cost constraints.

With the advent of portable testing instruments capable of producing results within minutes, which augment dipsticks and other noninstrumented testing systems (e.g., occult blood testing), point-of-care testing (POCT) (also referred to as near-patient testing or bedside testing) has evolved as one way to meet these demands. Because of the enormous consequences of unreliable test results, it is vital that results continue to be reliable and of high quality as these tests are transferred from the clinical laboratory to the point of care.

One of the challenges facing the healthcare community is acceptance of the idea that laboratory testing, traditionally performed by and under the supervision of trained laboratory personnel, will, in many instances, be performed by personnel not trained in clinical laboratory practice. This concern applies both within and outside the traditional laboratory community. It is the responsibility of the manufacturer to provide test systems capable of delivering reliable results when used properly by the testing personnel. Once the decision to offer POCT has been made, professionals in laboratory medicine should be involved to support and assess the results of these services.

POCT has been, and will continue to be implemented in a wide range of locations. It is up to each hospital, nursing home, emergency service provider, insurance company, home healthcare delivery network, etc., to assess its POCT needs. This document provides information on how to proceed in assessing those needs and in the evaluation and implementation of POCT.

It is the intent of the Subcommittee on Point-of-Care Testing that this guideline provides useful information to those wishing to perform POCT. The guideline was written under the assumption that its primary users will be nonlaboratory healthcare personnel. Therefore, we have attempted to provide definitions, procedures, and recommendations that are both educational and practical. In addition, the format is designed to be user-friendly and easy to follow.

This document replaces the approved guideline, AST2-A, which was published in 1995. Several changes have been made in this edition; chief among them is the introduction of the concept of alternative quality control (AQC), in Section 18.4.2, for point-of-care testing sites. The document has also been revised to include guidance for point-of-care programs outside the U.S., as well as updated regulatory recommendations for U.S.-based programs. This guideline also contains updated recommendations regarding patient specimen collection and identification (see Section 16) and a newly developed training checklist (see Appendix E).

Key Words

Calibration, point-of-care testing, quality assurance, quality control, safety

Point-of-Care *In Vitro* Diagnostic (IVD) Testing; Approved Guideline—Second Edition

1 Scope

There are many potential sites for POCT. Test operators may include nurses and physicians in acute care units in hospitals and emergency rooms; cardiac perfusionists in operating rooms; visiting home nurses in patients'/clients' homes; emergency medical technicians in ambulances; nurses in clinics, schools, and colleges; pharmacists and pharmacy technicians in pharmacies; and nonhealthcare workers at various employment settings, such as drug rehabilitation centers, law enforcement facilities, public screening sites, and insurance companies. A physician's office laboratory (POL) is another example of a setting for POCT. Patient self-testing and the handling of results generated by it are outside the scope of this document. Additionally, this guideline only applies to tests that involve the collection of patient specimens. Thus, analytical devices such as transcutaneous meters and continuous glucose monitoring devices are outside the scope of this document.

2 Introduction

Advances in technology and the implementation of microtechniques and portable instruments have made it possible to move laboratory testing closer to the patient/client. Point-of-care testing (POCT), is intended to provide more rapid and accessible test results than can be achieved in central or satellite laboratory settings. This is particularly important in critical care areas, such as the intensive care unit, emergency rooms, burn units, emergency transport vehicles, and operating rooms, as well as skilled nursing facilities, hospices, etc. POCT has also been used to expedite treatment decisions and provide convenience for the patient/client. The latter is significant in ambulatory outpatient settings (physician offices, clinics, etc.) where POCT has become an important form of diagnostic testing. The following guideline provides information and suggestions for good laboratory practice and for producing reliable test results, regardless of where testing is performed.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Infect Control Hosp Epidemiol.* 1996;17(1):53-80). For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to the most current edition of CLSI document M29—*Protection of Laboratory Workers From Occupationally Acquired Infections*.

4 Definitions

accuracy (of measurement) – 1) closeness of the agreement between the result of a measurement and a true value of the measurand (VIM93)¹; **2)** true or target value; freedom from error; **NOTE:** The accuracy of results can be measured by comparing them to results accepted as correct (e.g., standard methods), or by comparing them with those from another laboratory that uses a comparable method (this is "relative accuracy").